Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive cores-Reference-Cited by-同舟云学术

Dissecting the heterogeneity of localized prostate cancer risk groups through integration of percent of positive cores

Published:2018-06 Issue:15 Volume:14 Page:1469-1476
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Abdel-Rahman Omar¹²

Affiliation:

1. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy El Sayed Street, Cairo, 11566, Egypt

2. Department of Oncology, University of Calgary and Tom Baker Cancer Center, Calgary, Alberta T2N4N2, Canada

Abstract

Aim: To develop a modified risk stratification scheme for localized prostate cancer incorporating percent of positive cores (PPC). Methods: SEER database was accessed for eligible patients. Assessment of the prognostic value of PPC was conducted in a multivariate Cox regression model. A modified risk stratification scheme was proposed. Results: In a multivariate model, higher PPC was associated with worse cancer-specific survival (p < 0.0001). A modified risk-stratification scheme was proposed incorporating PPC. Concordance index was evaluated and the results were: D'Amico model: 0.782 (SE: 0.014; 95% CI: 0.755–0.810); modified model: 0.809 (SE: <0.001; 95% CI: 0.781–0.837). Conclusion: Integration of PPC into the risk stratification model for localized prostate cancer improves its performance.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2017-0596

Reference27 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Prostate cancer

3. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer

4. Validation of American Joint Committee on Cancer eighth staging system among prostate cancer patients treated with radical prostatectomy

5. Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to sub-classify stage IV?